Skip to content
Buy This GLP
← Research
Safety

Restarting a GLP-1 After a Break: What to Ask Your Prescriber

A patient who had tolerated semaglutide 2.4 mg for a year stopped for five weeks, resumed at the same dose, and developed severe symptoms the next day. Separate studies examined weight regain after discontinuation.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team8 min read
One patient, in order~1 yeartolerated at 2.4 mg, weight lost5 weeksno dosesrestartstraight back to 2.4 mg1 day latervomiting, diarrhea, electrolytesPrior tolerance did not carry across the break.

A case report describes severe nausea, vomiting and diarrhea one day after a patient resumed semaglutide following a five-week interruption [1]. For a single late dose, the guide to missed doses explains the instructions for specific products. Ask your prescriber how to resume treatment after a longer gap.

What happened

The patient had obesity, hypertension, high cholesterol and anxiety. She had been on semaglutide 2.4 mg for roughly a year, with good tolerance and successful weight loss. [1] The treatment was interrupted for five weeks during Ramadan.

She restarted at the dose she had been on. Within a day she had severe nausea, vomiting and diarrhea, and laboratory testing found significant electrolyte abnormalities. Severe gastrointestinal intolerance needing hospitalization is described in the literature as rare.

What the gap costs while it lasts

A model based on six studies with 1,776 participants estimated average regain of 1.04 kg per month after discontinuing semaglutide or tirzepatide [3]. The 95% credible interval runs 0.80 to 1.29, after an average loss of 15.35 kg. Observed follow-up ran from 4 to 52 weeks.

The analysis of weight regain after stopping describes an average across studies. It does not predict how much weight someone will regain during a five-week interruption.

The alternative to a full stop

The maintenance trial enrolled 441 participants. At week 60, it randomized 378 to continue their maximum tolerated dose of 10 or 15 mg, reduce to 5 mg, or switch to placebo [2]. Weight at week 112 sat 21.9% below baseline on the full dose, 16.6% at 5 mg, and 9.9% on placebo.

Under the trial protocol, rescue treatment began in 8% of the higher-dose group, 25% of the 5 mg group and 67% of the placebo group. The maintenance trial breakdown explains when participants qualified for rescue treatment. The trial compared maintenance regimens after initial weight loss.

Why this belongs on a price site

A late shipment or a lapse between prepaid plans can interrupt treatment. Use the term and prepay check to see what sellers disclose about the supply period and renewal. Confirm the next shipment date with the pharmacy if you are running low.

The review of refill gaps explains how researchers count treatment interruptions. Studies use refill windows of different lengths [4]. The same gap can count as continuous treatment in one study and an interruption in another.

Check the instructions for your product

The current U.S. prescribing information for Wegovy injection calls for restarting dose escalation at a lower dose after two or more consecutive missed doses. Confirm the instructions for your product and next dose with your prescriber.

Tell your prescriber how long the interruption lasted and what dose you last took. The Danish study of semaglutide maintenance doses recorded temporary pauses and permanent discontinuation separately. It did not compare restart schedules or establish which dose someone should resume.

Frequently asked

Can you restart a GLP-1 at the dose you stopped on?
One patient developed severe symptoms the day after resuming semaglutide 2.4 mg following a five-week gap. Re-escalation guidance depends on the product and the length of the gap, and it belongs to a prescriber.
How long a gap matters?
The reported case involved five weeks. The case report cannot establish a safe interval for resuming a previous dose.
What happens to weight during a break?
A pooled model estimated average regain of 1.04 kg per month after discontinuation. It cannot predict how much weight an individual will regain during a brief interruption.
What did the tirzepatide maintenance trial find?
Average weight at week 112 was 16.6% below the original baseline in the 5 mg group and 9.9% below baseline in the placebo group. Rescue treatment began in 25% and 67%, respectively.

Sources

  1. [1] Valizada H, et al. (2026). Severe Gastrointestinal Intolerance After Resuming Maintenance-Dose Semaglutide Following Ramadan-Related Treatment Interruption: A Case Report Cureus. PMID 42622003
  2. [2] Horn DB, Aronne LJ, Wharton S, Bays HE, le Roux CW, Srinath A (2026). Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial The Lancet. PMID 42119587
  3. [3] Kow CS, et al. (2026). Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-Analysis Endocrinology, Diabetes & Metabolism. PMID 42673571
  4. [4] Wang T, et al. (2026). Persistence in GLP-1-Based Therapy Among Adults with Obesity and Type 2 Diabetes: A Narrative Review of Definitions, Real-World Outcomes, and Determinants Current Diabetes Reports. PMID 42603234

More in Safety